PsiOxus initiates Phase II trial for wasting disease therapeutic
PsiOxus expects to recruit around 132 cachectic patients with colorectal and lung cancer in centers in Europe and Asia. The trial is designed to demonstrate reversal of weight
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.
The clinical trial will be conducted in Hospital Universitario Puerta de Hierro de Majadahonda in Madrid and Clinica Universidad de Navarra in Pamplona. According to researchers at the